IP Verse

Aminothiazole Derivatives Useful As Antiviral Agents - EP3440063

The patent EP3440063 was granted to Innovative Molecules on Aug 5, 2020. The application was originally filed on Apr 5, 2017 under application number EP17715722A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3440063

INNOVATIVE MOLECULES
Application Number
EP17715722A
Filing Date
Apr 5, 2017
Status
Opposition Rejected
Feb 9, 2024
Grant Date
Aug 5, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

AICURIS ANTI INFECTIVE CURESMay 5, 2021ETL PATENT UND RECHTSANWALTSGESELLSCHAFTADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2004006076
OPPOSITIONWO0053591
OPPOSITIONWO0147904
OPPOSITIONWO2010114930
OPPOSITIONWO2012160034
OPPOSITIONWO9724343
OPPOSITIONWO9942455

Non-Patent Literature (NPL) Citations (5) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- SCOTT et al., "Circumventing Seizure Activity in a Series of G Protein Coupled Receptor 119 (GPR119) Agonists", Journal of Medicinal Chemistry, (20141006), vol. 57, pages 8984 - 8998, XP055953786-
OPPOSITION- LÜCKING et al., "The Lab Oddity Prevails: Discovery of Pan-CDK Inhibitor (R)-S- Cyclopropyl-S-(4-{[4-{[(1R,2R)-2- hydroxy-1-methylpropyl]oxy}-50- (trifluoromethyl)pyrimidin-2- yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer .", ChemMedChem, (20130513), vol. 8, no. First published, pages 1067 - 1085, XP055953788
OPPOSITION- GOLDBERG et al., "General synthetic strategies towards N-alkyl sulfoximine building blocks for medicinal chemistry and the use of dimethylsulfoximine as a versatile precursor", Tetrahedron, (20140307), vol. 70, doi:10.1016/j.tet.2014.06.120, pages 6613 - 6622, XP029014827
OPPOSITION- KAUFMAN et al., "Efficacy of Helicase- Primase Inhibitor in Animal Models of Ocular Herpes Simplex Virus Type 1 Infection", Journal of Ocular Pharmacology and Therapeutics, (20080123), vol. 24, doi:10.1089/jop.2007.0084, pages 34 - 42, XP055362432
OPPOSITION- BETZ et al., "Potent In Vivo Antiviral Activity of the Herpes Simplex Virus Primase- Helicase Inhibitor BAY 57-1293.", Antimicrobial Agents and Chemotherapy, (20020601), vol. 46, doi:10.1128/AAC.46.6.1766-1772.2002, pages 1766 - 1772, XP055012766

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents